For thirty minutes at a time, sobbers sit with music, written prompts and comfy furniture, all meant to bring up the waterworks.
SAN ANTONIO — Ozempic may be all the rage with those looking to lose weight. But as Jeremy Baker, reports another medication may give some an upper leg on lowering their weight. That medication is Mounjaro. And the findings were released this month in the JAMA Internal Medicine medical journal.
Dr. Carolina Solis-Herrera, the Chief of the Endocrinology Division at UT Health San Antonio told us,"Talking about a clinical trial. Head to head with semaglutide, versus terzepatide. It did show a, gently, significant increase in weight loss." Researchers looked at more than 18,000 adults. Each patient received tirzepatide, the active ingredient in Mounjaro, or semaglutide, the active ingredient in Ozempic. They were given the medications between May of 2022 and September of 2023 and found that most benefited from a 5 percent weight loss, but more of a loss with tirzepatide. The reason for the increased weight loss? The way the drug communicates with your body. Dr.
That means the way your body responds differs from Ozempic. But you have to take into account your heart health too. Dr. Solis-Herrera said,"Terzepadide does not have a cardiovascular protection indication versus semaglutide. Semaglutide does have an indication for cardiovascular protection in patients with type two diabetes."
But the doctor says both meds work just fine. Dr. Solis-Herrera told us,"So bottom line, really, they're both very good. They're both very potent. And it's up to the clinician up to the doctor to decide what's most important for the patient." WHO and Eli Lilly caution patients against falling for fake versions of popular weight-loss drugsKENS would like to send you push notifications about the latest news and weather.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Study finds Mounjaro 'significantly more' effective than Ozempic for weight lossOverweight and obese adults using popular diabetes medications to suppress their appetites are 'significantly more likely' to shed pounds with Eli Lilly's Mounjaro than with Novo Nordisk's Ozempic, a new study has found, a result that could have major implications for one of the hottest new markets in the pharmaceutical field.
Read more »
Mounjaro leads to significantly more weight loss than Ozempic, study suggestsPeople taking tirzepatide injections lost more weight and were more likely to reach specific weight loss targets than those taking semaglutide, according to a new study.
Read more »
Ozempic vs. Mounjaro: New study reveals which is better to combat obesityBeyond Traditional Diet Pills: Groundbreaking New Weight Loss Drug Is More Effective Than Current Treatments
Read more »
Mounjaro leads to significantly more weight loss than Ozempic, study suggestsWith more people using drugs like Ozempic and Wegovy for weight loss, food companies are paying close attention and trying to adapt to changing eating habits.
Read more »
Mounjaro leads to significantly more weight loss than Ozempic, study suggestsPeople taking tirzepatide injections lost more weight and were more likely to reach specific weight loss targets than those taking semaglutide.
Read more »
Ozempic vs. Mounjaro: Head-to-Head Study Shows Weight Loss WinnerA new study found that tirzepatide, the active ingredient in Mounjaro, caused more weight loss than Ozempic's semaglutide. Experts said the study adds to a body of research doctors are increasingly relying on to guide people with obesity and type 2 diabetes.
Read more »